Why is Inovio Pharmaceuticals facing a securities class action lawsuit?

Investors allege Inovio misled the market about manufacturing readiness for its CELLECTRA device and overstated the likelihood and timing of FDA approval for INO-3107, harming shareholders when the risks became clear.

What problems are alleged with Inovio’s CELLECTRA manufacturing?

The lawsuit claims manufacturing for the CELLECTRA device was deficient, meaning Inovio lacked the capability to support a timely FDA biologics license application tied to its lead drug candidate.

What is INO-3107 and why does FDA approval matter to investors?

INO-3107 is Inovio’s experimental therapy and a key growth driver. FDA approval, including accelerated or priority review, would be critical to commercialization, revenue, and company valuation.

What are investors alleging about Inovio’s FDA submission timeline?

Investors allege Inovio lacked sufficient information to support submitting the INO-3107 BLA by the expected timeframe, making public statements about regulatory progress misleading.

What is the deadline to seek lead plaintiff status in the Inovio lawsuit?

Investors seeking to serve as lead plaintiff in the federal securities class action against Inovio Pharmaceuticals must file a motion by April 7, 2026, to preserve their right to represent the class.

Inovio Pharmaceuticals, Inc - Faruqi & Faruqi LLP

Inovio Pharmaceuticals, Inc

Join Action

Case Details

Ticker INO

Class Period 10/10/2023 - 12/26/2025

Lead Plaintiff Deadline 04/07/2026

Days Left to Seek Plaintiff

If you are a Inovio Pharmaceutical investor who suffered a loss and would like to learn more, you can provide your information below:

If you purchased or acquired securities in Inovio between October 10, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Inovio Pharmaceuticals, Inc. (“Inovio” or the “Company”) (NASDAQ: INO) and reminds investors of the April 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) manufacturing for Inovio’s CELLECTRA device was deficient; (2) accordingly, Inovio was unlikely to submit the INO-3107 BLA to the FDA by the second half of 2024; (3) Inovio had insufficient information to justify the INO-3107 BLA’s eligibility for FDA accelerated approval or priority review; (4) accordingly, INO-3107’s overall regulatory and commercial prospects were overstated; and (5) as a result, Defendants’ public statements were materially false and misleading at all relevant times.

Join Action

Inovio Pharmaceuticals, Inc

Monetary Losses ($) *

Website URL

First Name *

Last Name *

Telephone *

Email *

Street Address

City

State

Zip Code

Purchases

1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Purchases Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Sales

1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date
1	Sales Options Price per Share Date # of Shares Principal Amount Amount Paid Series or Cusip # of Contracts Price per Contract Exercise Price Expiration Date

Add Row

Upload your trades here:

Accepted file types: xls, xlsx, doc, docx, pdf, jpg, jpeg, png, Max. file size: 50 MB, Max. files: 5.
You may redact account numbers from your uploaded documents.

File name:

File size:

Select File

Does not establish an attorney-client relationship *

By clicking this box, I acknowledge that this form is not intended to and does not establish an attorney-client relationship between myself and Faruqi & Faruqi LLP, and that the submission or receipt of information via this form, e-mail or telephone does not create an attorney-client relationship.

Case

Users to notify